Discontinuation of Antiplatelet Study Medication and Risk of Recurrent Stroke and Cardiovascular Events: Results from the PRoFESS Study

Publisher： Karger

E-ISSN： 1421-9786|35|6|538-543

ISSN： 1015-9770

Source： Cerebrovascular Diseases, Vol.35, Iss.6, 2013-06, pp. : 538-543

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Discontinuation of Antiplatelet Treatment and Risk of Recurrent Stroke and All-Cause Death: A Cohort Study

By  

Neuroepidemiology, Vol. 43, Iss. 1, 2014-10 ,pp. : 57-64

Karger

Access to resources Recommend Favorite

Risk Factors and Treatment at Recurrent Stroke Onset: Results from the Recurrent Stroke Quality and Epidemiology (RESQUE) Study

By  

Cerebrovascular Diseases, Vol. 25, Iss. 3, 2008-01 ,pp. : 254-260

Karger

Access to resources Recommend Favorite

Risk of Recurrent Cerebrovascular Events in Patients with Cryptogenic Stroke or Transient Ischemic Attack and Patent Foramen Ovale: The FORI (Foramen Ovale Registro Italiano) Study

By  

Cerebrovascular Diseases, Vol. 31, Iss. 2, 2010-11 ,pp. : 109-116

Karger

Access to resources Recommend Favorite

Risk Factors for Cardiovascular Events in Japanese Patients Treated with Fluvastatin from the Long-Term Event Monitoring (LEM) Study

By  

Current Vascular Pharmacology, Vol. 10, Iss. 2, 2012-03 ,pp. : 178-186

Bentham Science Publishers

Access to resources Recommend Favorite

Trends in Five-Year Survival and Risk of Recurrent Stroke after First-Ever Stroke in the Perth Community Stroke Study

By  

Cerebrovascular Diseases, Vol. 19, Iss. 3, 2005-03 ,pp. : 179-185

Karger

Access to resources Recommend Favorite